57370-13-5

Usage

Uses

Used in Cardiology:
2,6-BIS(2-HYDROXYETHYLAMINO)-4,8-DIPIPERIDINOPYRIMIDO(5,4-D)PYRIMIDINEDIPYRIDAMOLE is used as an antiplatelet agent for preventing the formation of blood clots in patients at risk of stroke or heart attack. It is often combined with other medications, such as aspirin, to further reduce the risk of blood clots in individuals who have undergone cardiac stent placement or heart valve replacement.
Used in Diagnostic Procedures:
In the field of cardiology, 2,6-BIS(2-HYDROXYETHYLAMINO)-4,8-DIPIPERIDINOPYRIMIDO(5,4-D)PYRIMIDINEDIPYRIDAMOLE is used as a diagnostic aid for coronary artery disease. It is sometimes administered in conjunction with a stress test to assess the blood flow to the heart, providing valuable information for the diagnosis and treatment of this condition.
Formulations:
Dipyridamole is available in both tablet and injectable forms, allowing for flexible administration as directed by healthcare providers. It is typically prescribed to be taken multiple times daily to maintain its therapeutic effects.

Upstream product

• 7139-02-8 2,6-dichloro-4,8-bis(piperidin-1-yl)pyrimido[5,4-d]pyrimidine 
• 141-43-5 ethanolamine 
• 110-89-4 piperidine 
• 32980-71-5 2,4,6,8-Tetrachloro-pyrimido[5,4-d]pyrimidine 

Relevant academic research and scientific papers

Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors

Dipyridamole (Persantine) is a clinically used vasodilator with equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent than the prototype ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR). Dipyridamole is a good candidate for further exploration because it is a non-nucleoside and has a proven record of safe use in humans. A series of dipyridamole analogues were synthesized with systematic modification and evaluated as ENT1 inhibitors by flow cytometry. Compounds with much higher potency were identified, the best being 2,6-bis(diethanolamino)-4,8-diheptamethyleneiminopyrimido[5,4-d]pyrimidine (13) with a Ki of 0.49 nM compared to a Ki of 308 nM for dipyridamole. Compound 13 is similar in potency to the prototype potent ENT1 inhibitor NBMPR (0.43 nM). For the first time, a dipyridamole analogue has been identified that is equipotent with NBMPR. The SAR indicated that diethanolamine substituted analogues were more active than monoethanolamine compounds. Also, free hydroxyl groups are not essential for activity.

Structure-activity relationships of pyrimido-pyrimidine series of 5-lipoxygenase inhibitors

A series of pyrimido-pyrimidine compounds were synthesized and a SAR study was conducted for 5-LO inhibition using a broken cell preparation from RBL-1 cells. In this series compound 21 was found to be a potent 5-LO inhibitor in vitro.